source
- Novo says launch of obesity drug CagriSema in Europe delayed by a couple of yearsNovo Nordisk announced it will not bring its obesity candidate CagriSema to European markets for the next few years. The statement came from the company's outgoing chief financial officer, Karsten…
- Sanofi halts Nurix STAT6 degrader program two months after phase-1 startSanofi announced it is ending its collaboration with Nurix on a STAT6 degrader, just two months after the drug entered a phase-1 study. The two companies have worked together since 2019, with Sano…